Tenax Therapeutics (TENX) Competitors $6.14 +0.14 (+2.25%) Closing price 05/21/2025 03:44 PM EasternExtended Trading$6.09 -0.05 (-0.80%) As of 05/21/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TENX vs. IMUX, CRDL, ZNTL, VXRT, ORMP, PLRX, TIL, XBIT, SAVA, and GALTShould you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Immunic (IMUX), Cardiol Therapeutics (CRDL), Zentalis Pharmaceuticals (ZNTL), Vaxart (VXRT), Oramed Pharmaceuticals (ORMP), Pliant Therapeutics (PLRX), Instil Bio (TIL), XBiotech (XBIT), Cassava Sciences (SAVA), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. Tenax Therapeutics vs. Immunic Cardiol Therapeutics Zentalis Pharmaceuticals Vaxart Oramed Pharmaceuticals Pliant Therapeutics Instil Bio XBiotech Cassava Sciences Galectin Therapeutics Immunic (NASDAQ:IMUX) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings, community ranking and analyst recommendations. Is IMUX or TENX more profitable? Tenax Therapeutics' return on equity of -46.00% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets ImmunicN/A -169.55% -118.96% Tenax Therapeutics N/A -46.00%-42.65% Do insiders and institutionals have more ownership in IMUX or TENX? 51.8% of Immunic shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 3.0% of Immunic shares are held by insiders. Comparatively, 3.7% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate IMUX or TENX? Immunic currently has a consensus target price of $13.20, suggesting a potential upside of 1,334.78%. Tenax Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 185.25%. Given Immunic's higher probable upside, research analysts plainly believe Immunic is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media refer more to IMUX or TENX? In the previous week, Tenax Therapeutics had 17 more articles in the media than Immunic. MarketBeat recorded 21 mentions for Tenax Therapeutics and 4 mentions for Immunic. Immunic's average media sentiment score of 0.75 beat Tenax Therapeutics' score of 0.09 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer IMUX or TENX? Tenax Therapeutics received 34 more outperform votes than Immunic when rated by MarketBeat users. However, 65.50% of users gave Immunic an outperform vote while only 54.28% of users gave Tenax Therapeutics an outperform vote. CompanyUnderperformOutperformImmunicOutperform Votes11265.50% Underperform Votes5934.50% Tenax TherapeuticsOutperform Votes14654.28% Underperform Votes12345.72% Which has better earnings and valuation, IMUX or TENX? Tenax Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunicN/AN/A-$93.61M-$1.23-0.75Tenax TherapeuticsN/AN/A-$7.71M-$2.48-2.47 Which has more risk & volatility, IMUX or TENX? Immunic has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. SummaryImmunic beats Tenax Therapeutics on 8 of the 15 factors compared between the two stocks. Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENX vs. The Competition Export to ExcelMetricTenax TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.45M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-2.478.9226.8419.71Price / SalesN/A253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.236.466.794.50Net Income-$7.71M$143.98M$3.23B$248.18M7 Day Performance7.63%2.03%1.53%0.20%1 Month Performance20.29%4.11%10.05%12.37%1 Year Performance69.48%-2.87%16.71%7.04% Tenax Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENXTenax Therapeutics2.0791 of 5 stars$6.14+2.3%$17.50+185.2%+67.2%$25.45MN/A-2.479Analyst RevisionIMUXImmunic2.4114 of 5 stars$0.99-2.3%$13.20+1,237.8%-27.6%$94.54MN/A-0.8070Earnings ReportGap DownCRDLCardiol Therapeutics1.6139 of 5 stars$1.13-1.7%$8.40+643.4%-52.3%$93.35MN/A-2.9020ZNTLZentalis Pharmaceuticals2.0841 of 5 stars$1.29+4.9%$8.24+539.1%-89.6%$92.82M$67.43M-0.52160News CoverageEarnings ReportAnalyst RevisionVXRTVaxart2.3822 of 5 stars$0.41-3.5%$3.00+640.7%-46.8%$92.42M$28.70M-0.99120ORMPOramed Pharmaceuticals1.7549 of 5 stars$2.24-0.4%N/A-8.7%$91.50M$1.34M20.3610Earnings ReportPLRXPliant Therapeutics4.3244 of 5 stars$1.47+4.3%$13.31+805.6%-90.9%$90.24M$1.58M-0.4490Positive NewsGap DownTILInstil Bio2.2194 of 5 stars$13.68+3.4%$114.00+733.3%+45.2%$89.73MN/A-1.18410Gap DownXBITXBiotech0.6102 of 5 stars$2.91+5.1%N/A-67.2%$88.72M$4.01M-2.69100Earnings ReportSAVACassava Sciences3.8201 of 5 stars$1.83+3.4%$54.50+2,878.1%-90.8%$88.40MN/A-1.3330GALTGalectin Therapeutics1.2204 of 5 stars$1.39+0.7%$11.00+691.4%-60.4%$87.82MN/A-1.909Earnings Report Related Companies and Tools Related Companies Immunic Alternatives Cardiol Therapeutics Alternatives Zentalis Pharmaceuticals Alternatives Vaxart Alternatives Oramed Pharmaceuticals Alternatives Pliant Therapeutics Alternatives Instil Bio Alternatives XBiotech Alternatives Cassava Sciences Alternatives Galectin Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TENX Stock Free TENX Stock Alerts